Key facts
- Seven large drugmakers say AI now designs molecules, sorts candidates and flags safety risks, not just prepares filings.
- Novartis President of Biomedical Research Fiona Marshall said time from project start to a drug candidate fell from three years to about 18 months to two years.
- Sanofi R&D executive Matt Truppo said he expects AI to cut early-discovery timelines by 20% to 25% within two years.
- GSK Chief Scientific Officer Tony Wood said he views Anthropic as another competitor; Bristol Myers and Novo Nordisk see AI companies more as partners.
- Novo Nordisk and Sanofi said they do not give proprietary data to frontier labs to train AI models.
- Anthropic did not respond to a request for comment on its acquisition plans and its relationship with drugmakers.
Seven of the world's largest pharmaceutical companies say artificial intelligence has sped up early-stage drug development in 2026, cutting by as much as half the time needed to produce new molecules and move them into clinical testing, according to their top scientists. GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca and Sanofi told Reuters they have moved past using AI for tasks such as preparing regulatory filings and now use it to design molecules, pick the most promising ones and identify safety risks.
"There is no part of the discovery through development pipeline where we are not using AI," AstraZeneca executive Sharon Barr said. Sanofi said it saved at least a year developing asthma treatment lunsekimig by using an AI-enabled approach that let it skip a dose-selection study. Novartis said AI tools helped it find five targets it prioritized for kidney disease treatments. Bristol Myers said one of its sickle cell anemia candidates would not have been developed without its AI systems.
Novo Nordisk said AI cut the number of cycles of designing, manufacturing and testing new molecules from around eight to three and each cycle from eight weeks to four. Novartis President of Biomedical Research Fiona Marshall said the average time from project start to a drug candidate has gone from three years to about 18 months to two years. Sanofi's Matt Truppo, global head of computational and AI strategy for R&D, said he expects AI to cut early-discovery timelines by 20% to 25% within two years and perhaps by half within five years across more than 100 programs.
The drugmakers are weighing Anthropic as a rival, partner or both. The AI company held a $1.5 trillion initial public offering this week, opened its own laboratory and announced other investments. On Thursday, CEO Dario Amodei spoke at the Nasdaq before shares began trading, recalling his father dying of a disease shortly before a cure was found. "I believe these processes can be substantially accelerated by AI," he said. Anthropic launched research-focused AI software called Claude Science and added Novartis CEO Vas Narasimhan to its board; Novo Nordisk uses Anthropic models in its R&D work.
GSK Chief Scientific Officer Tony Wood said he views Anthropic "as another competitor," while Bristol Myers and Novo Nordisk see AI companies more as partners. Eli Lilly's Aliza Apple, who runs its TuneLab program giving smaller biotechs access to Lilly's internal AI models, said claims that the technology can cure all disease overstate current capabilities. "It would be great for them to cure one, and then let's talk about the rest," she said. Novo Nordisk and Sanofi said they do not provide proprietary data to frontier labs to train their models.
AI-enabled drugs in clinical testing have climbed only incrementally. In March, researchers identified 129 drug candidates across 69 companies, up from around 117 eight months earlier, with most programs still in early-stage development. Dr. Waqas Haque, an oncology fellow at the University of Chicago who was on the team that compiled the data, said he expects an uptick in AI drugs reaching preclinical and clinical stages over the next one to three years but does not know if they will be more successful or approved quicker. Anthropic did not respond to a request for comment on its acquisition plans and its relationship with drugmakers.